Anti-angiogenic agents have recently been used in the treatment of cancer in combination with chemotherapy as angiogenesis is very well documented to be a powerful control point in tumour development. The growth of uterine fibroids was recently shown to be dependent on angiogenesis and different angiogenic factors involved in uterine fibroids are expressed in leiomyoma. Uterine fibroid (uterine leiomyomas) is one of the causes of infertility and is associated with recurrent miscarriages. Pathologically uterine fibroid is a benign tumours arising from the uterine myometrial compartment. Common treatments for fibroids include pharmacotherapy and non-pharmacotherapy treatments partly via anti-angiogenic mechanisms. In conclusion, direct anti-angiogenic agents may contribute to fibroid treatment. Unfortunately, there lacks good in vivo and in vitro models of uterine fibroid. Further research into developing experimental model to study uterine fibroid will aid in better understanding this disease.
Introduction
e link between angiogenesis and tumours was rst described in 1968 by Algire and Chalkley (Tonini et al., 2003) . Currently, angiogenesis is very well-documented as a powerful control point in tumour development. Disordered structure in a tumour is due to an imbalance in angiogenic factors, like vascular endothelial growth factor (VEGF) and angiopoietins (Baish and Jain, 2000) .
Angiogenesis is the result of the coordination between induced angiogenic and anti-angiogenic factors (Makrilia et al., 2009 ). e growth, progression and metastasis of a tumour can be controlled by inhibiting the angiogenic process and this can be used for treatment of tumours as an alternative or additive therapy to conventional chemotherapy. In 2004, anti-angiogenic therapies in combination with chemotherapy for cancer began with the approval of bevacizumab by the US Food and Drug Administration (FDA) (Makrilia et al., 2009) . Recently, angiogenesis was linked to uterine broids as a regulation of smooth muscle cell proliferation.
e smooth muscle cell (SMC) proliferation is altered in broids compared with the adjacent myometrium.
ere is an exaggerated response to oestrogen, which promotes proliferation. Progesterone also appears to play a key role in stimulating SMC proliferation. A variety of growth factors (TGF-b, EGF, bFGF, IGFs, PDGF) have di erential e ects on broids compared with normal myometrium via a variety of mechanisms including alteration of receptor levels and signalling pathways. (Tal and Segars, 2013 Uterine broids are known as uterine leiomyomas arising from the uterine myometrial compartment. ey are the most common tumours of the female reproductive tract (Walker et al., 2003) . Uterine broid can be pathologically classi ed as solid tumour diseases as they have a relatively low mitotic index and retain their smooth muscle phenotype. Unfortunately, they can cause signi cant morbidity and even mortality. Uterine broids clinically a ect 25-50% of all women (Walker et al., 2003) . ey occur with a remarkable frequency in more than 70% of reproductive-aged women (Cramer and Patel, 1990 Relatively little is known of the biology, aetiology and patho- likely to synergize to support tumor growth (Tsibris et al., 2003) .
In a study of genome-wide miRNA expression patterns in uterine broids and myometrium using Solexa high-throughput sequencing, a study found more than 55 miRNAs which were di erentially expressed. e top ve signi cantly de-regulated miRNAs in uterine broids that was found in their libraries were miR-363, miR-490, miR-137, miR-217 and miR-4792. It was also observed "isomiRs" with higher copy number than referenced mature miRNA speci c for the leiomyoma libraries, which have a potential role in tumorigenesis (Georgieva et al., 2012) . In study for quanti cation of transcript expression levels in uterine broids relative to normal myometrium using Model-based expression analysis revealed that of the 22,500 transcripts represented on the arrays, 226 genes were found to be dysregulated by a >1.5-fold change between leiomyoma and normal myometrium. Moreover, in this study, the authors identi ed many dysregulated apoptosis-related genes. Of particular interest was TRAIL (Tumor necrosis factor-related apoptosis-inducing ligand) and Ask1. Numerous di erentially expressed proliferation genes, including TGFB1, PDGFC, and two dual speci city phosphatases were also identied. ese genes may play a signi cant role in the development of leiomyomas from normal uterine tissue. e deregulation of apoptotic and proliferative processes has been hypothesized to be pathway (Tadakawa et al., 2015) . e Eker rat model and tumour-derived ELT cell lines have been used extensively to identify therapeutic strategies for uterine broids and to investigate the aetiology of this disease. 
Ex vivo Experimental modules
Estrogen will be administered to animals, then the concentration of estrogen receptors (ERs) in myometrium will be determined. In general, both ERa and ERb are present in higher levels in leiomyoma tissue compared with myometrium. 45 ERb appears to be ubiquitous to all cell types within myometrium, whereas ERa has a variable expression in di erent cell types. is nding indicates that ERb is more relevant to the development and growth of leiomyomas. Another nding of this study implies that oestrogen acts upon growth factors, cytokines, histamine and heparin to promote cell proliferation .
In vivo Experimental modules
Five animal models have been found in the literature review which include inoculated nude mice with ELT-3 cells (Vaezy et al., 2000) , Eker Rat Model (Yeung et al., 1995) , Monosodium glutamate (MSG) treated rats Obochi et al., 2009 ), Dehydroepiandrosterone (DHEA) treated rats (Zhang et al., 2013) and guinea pig models of estrogen-induced uterine broids (Porter et al., 1995) . Animals in which a tumour developed were randomly assigned to one of three groups: no treatment (positive control), di erent groups of treatment, or sham treatment.
Eker Rat as second model
e Eker rat is the only animal model that spontaneously develops uterine broids . gene silencing, and point mutations (Yeung et al., 1995) . However this animal model has limitation, Eker rat is the genetic experimental model for uterine broids which accurately describes cases where patients have "genetic" syndromes that include broid development, such as hereditary broids, but is not suitable for modelling uterine broids that are independent of genetics such as sex hormone levels and environmental factors (Walker et al., 2003) . e third animal model is Monosodium glutamate (MSG)-induced broids in rats by increased serum estrogen and cholesterol: Di erent dosages of MSG have been used to induce broids in rats. e dosages which were found include 100 mg/kg (Obochi et al.., 2009) , 200 mg/kg (Ogunlabi et al., 2014) showed upregulated expression in uteri of these rats. Similarly, mRNA levels of bronectin and angiotensin-II showed increased expression (Zhang et al., 2013) . e h animal model, guinea pig model of estrogen-induced uterine broids: Guinea pig aged ranging from young to old with average age from 4-6 months to 2-2.5 years old received two E2 in the subcutaneous space of the intrascapular area 7-10 days a er a bilateral oophorectomy or sham operation for three months. e parameters can be evaluated serum sex hormones and uterus tissue (Porter et al., 1995) .
Discussion
Recent study about anti-angiogenic agents in combination with standard chemotherapy for the treatment of cancer indicated that direct anti-angiogenic agents may contribute to uterine broid treatment (Ferrara and Kerbel, 2005) . e current pharmacotherapy for uterine broids showed many limitation because of low speci city which leads to serious side e ects. e GnRH-agonists e ectively shrink uterine broid volume due to the hypo-estrogenic state induced (Andreyko et al., 1987; Adamson, 1992) and it can cause a signi cant loss of bone mineral density due to extended mechanism of action (Dawood et al., 1989) . Because of this side e ects, treatments are limited to six months in length .
Moreover, cessation of therapy results in regrowth of uterine broids, o en rapidly (Friedman et al., 1990 ). receptors, apoptotic activity of tested compounds, anti-angiogenics activity, protein expression, and gene expression in these uterine broids. e in vivo experimental models used were ve di erent animal models that include inoculated nude mice with ELT-3 cells (Vaezy et al., 2000) , the Eker Rat Model (Yeung et al., 1995) , rats treated with monosodium glutamate (MSG) (Obochi et al.., 2009) , rats treated with dehydroepiandrosterone (DHEA) (Zhang et al., 2013) and a guinea pig model of estrogen-induced uterine broids (Porter et al., 1995) .
Conlusion
In conclusion, direct anti-angiogenic agents may contribute to broid treatment. However, there still exists a lack of good in vivo and in vitro models of uterine broid. Further research in order to develop experimental models will help drive research forward to study the anti-angiogenic e ects of various treatments on uterine broid.
